Bristol-Myers Squibb Company
Bristol-Myers Squibb Company sells branded specialty pharmaceuticals and innovative therapies (including immuno-oncology, hematology, cardiovascular, immunology, and neuroscience drugs) to hospitals, pharmacies, wholesalers, and government entities via a global distribution network by developing, licensing, manufacturing, and commercializing proprietary medicines that address serious diseases and unmet medical needs.
LOCKED
Market: NormalKey Catalysts & Risks
The forward setup is dominated by a dense set of late-stage readouts and by the approaching loss of exclusivity on the largest products. The most consequential near-term catalyst is the remaining milvexian Phase 3 program in secondary stroke prevention and atrial fibrillation, expected to report between late 2026 and the first half of 2027 after the acute-coronary-syndrome study was stopped for futility; positive data would open a large cardiovascular opportunity, while another neutral result would remove a key growth pillar. Cobenfy is the second major swing factor, with the Alzheimer's disease psychosis program continuing after the company adjusted the study following site-level irregularities, and success there would materially strengthen the rationale for the Karuna acquisition. A group of pivotal readouts for the oral CELMoD agents in multiple myeloma, the pulmonary fibrosis candidate, and the BioNTech-partnered bispecific is also expected over roughly the next two years and could add new launch opportunities. On the downside, the company has guided to a sharp decline in Eliquis as exclusivity ends in the United States and erodes sooner in Europe, which will pressure revenue and margins regardless of pipeline success.
The most material structural risk is the loss of exclusivity on its largest products, Eliquis and Opdivo, with United States protection ending later this decade and European erosion already under way; management has characterised the coming decline as rapid and steep, which structurally shrinks the cash-generating base that funds research and shareholder returns. A second structural issue is regulatory pricing exposure, since Eliquis is subject to government-negotiated pricing in the largest market and additional products are entering that framework, permanently limiting pricing power. The company has also disclosed a long-running dispute with the Internal Revenue Service over transfer pricing and related matters, with a possible reduction in unrecognized tax benefits over the next year and the potential for a material impact if resolved unfavourably. Together these factors mean the equity case depends heavily on pipeline replacement rather than on the durability of the existing franchise, which can keep a discount on the shares until new products visibly offset the declines.
Research refreshed: 2nd of October 2026
KPIs and Peer Benchmarks
| EV | P/E | Net Debt/EBIT | Revenue Growth | |
|---|---|---|---|---|
| AbbVie Inc. (ABBV) | 529B | 74.04 | 3.40 | 8.6% |
| Amgen Inc. (AMGN) | 261B | 24.85 | 3.42 | 9.9% |
| AstraZeneca… (AZN) | 274B | 23.65 | 1.98 | 8.6% |
| Gilead Scie… (GILD) | 207B | N.M. | N.M. | 2.4% |
| GSK plc (GSK) | 115B | 14.96 | 1.89 | 4.1% |
| Johnson & J… (JNJ) | 646B | 29.60 | 1.09 | 6.0% |
| Eli Lilly a… (LLY) | 1.12T | 38.24 | 1.16 | 44.7% |
| Merck & Co.… (MRK) | 403B | 114.52 | 4.26 | 1.2% |
| Novartis AG (NVS) | 308B | 21.31 | 2.54 | 6.0% |
| Pfizer Inc. (PFE) | 221B | 36.73 | 3.89 | -1.6% |
| Regeneron P… (REGN) | 75.3B | 17.55 | -0.12 | 1.0% |
| Sanofi (SNY) | 115B | 21.65 | 1.71 | 5.5% |
| Vertex Phar… (VRTX) | 126B | 29.72 | -0.86 | 9.6% |
| Bristol-Mye… (BMY) | 159B | 13.47 | 2.47 | -0.2% |
AI Opinion
Fundamentals
BUY: Q2 FY2026 materially strengthens the portfolio-transition case: growth products rose 14% to $7.6B, nearly 60% of revenue, with 10 products posting double-digit growth. This addresses older concerns about undisclosed product momentum, but does not eliminate the central risk: management expects a $1.5B-$2B Eliquis revenue step-down in 2027. Successful launches and pipeline conversion must offset legacy erosion.
Peer Comparison
BMY outperforms only approximately 23.1% of 13 peers on combined growth and quality, indicating weak relative positioning despite strong profitability. The latest growth-portfolio acceleration improves the forward narrative but does not establish an updated peer ranking. No reliable peer valuation supports a relative-multiple argument.
Macro Environment
Elevated 5.29% Treasury yields limit valuation expansion, while BMY's approximately 4.08% trailing dividend yield offers no Treasury yield premium. Serious-disease exposure supports relative demand resilience, but supplied macro data do not establish prescription sensitivity. Company-specific pricing and reimbursement mechanics matter more: H2 2026 Eliquis benefits from CPI-penalty elimination, while European patent expiry in mid-Q4 and the 2027 revenue step-down create direct headwinds. Mixed healthcare breadth is contextual, not a rating driver.
Key Metrics
EV/EBITDA is 9.53x versus a 12.38x historical median; historical median fair value of $92.06 implies 49.5% price upside, but low fair value of $60.26 is 2.1% below the current price, providing little downside cushion. Operating margin is 28.27%, FCF margin 23.26% and ROIC 15.47%; TTM revenue growth of 3.1% contrasts with stronger Q2 product momentum. Historical fair value is a valuation reference, not a 12-month forecast.
Insider Activity
Modestly bearish confirmation: three insiders sold $2.29M over 12 months, with no purchases shown. The recent $403,498 officer sale reduced that holding 25%; the earlier CFO sale reduced his holding 15.8%. No cluster exists, and discretionary intent is unproven; this tempers conviction without overriding valuation and operating evidence.
Income Statement
Q2 revenue grew approximately 5%-6%, and management raised FY2026 revenue and adjusted EPS guidance. Eliquis grew 21%, with FY2026 growth guided to 20%-25%; Reblozyl, Breyanzi, Camzyos and Sotyktu delivered strong growth. However, TTM EBITDA rose only 1.5% versus operating-income growth of 35.2%, and Q2 margin expansion largely reflected lower other operating expenses rather than stronger gross economics. Opdivo declined 4%, partly reflecting conversion to Qvantig rather than purely lost franchise demand.
Cash Flow
TTM FCF of $11.4B covers $5.1B dividends approximately 2.2x, supporting the income component. However, OCF fell 19.6% to $12.8B, FCF declined $3.1B and cash fell $3.9B amid working-capital outflows, acquisitions and debt repayment. Q2 OCF of $3.4B confirms substantial ongoing generation, not yet a sustained recovery; improving working-capital conversion is a key confirmation metric.
Balance Sheet
Net debt of $32.1B is approximately 1.9x TTM EBITDA, manageable but material. Debt declined $6.1B year over year; the earnings call reported another $1.2B Q2 repayment and $11.5B cash and marketable securities. Falling cash, acquisition commitments and undisclosed debt maturities constrain flexibility; goodwill and intangibles represent 44.7% of assets.